Sage Therapeutics, Inc. (SAGE) managed to rebound with the stock climbing 11.75% or $5.57 to close the day at $52.99 on lower than average trading volume of 2.44M shares, compared to its three month average trading volume of 491.74K. The based company has been outperforming the biotechnology companies by 3.1422% for last three months and its recent gains have pushed the stock slightly up 3.78% YTD, versus the biotechnology industry which is down -2.82% for the same period. The RSI of 63.07 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedation are desirable prior to the introduction of general anesthesia. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cynosure, Inc. (CYNO) had a light trading with around 2.43M shares changing hands compared to its three month average trading volume of 648.92K. The stock traded between $49.25 and $52.9 before closing at the price of $51.5 with -6.45% change on the day. The Westford Massachusetts 01886 based company is currently trading 49.41% above its 52 week low of $34.47 and -7.94% below its 52 week high of $55.94. Both the RSI indicator and target price of 55.59 and $59.13 respectively, lead us to believe that it should be put on hold over the coming weeks.
Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. The company’s aesthetic treatment systems utilize a range of energy sources, including Alexandrite, diode, Nd: YAG, pulse dye, Q-switched lasers, intense pulsed light, and radiofrequency (RF) technology. It offers Elite product line for hair removal, and treatment of facial and leg veins and pigmentations; SmartLipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; Cynergy product line for the treatment of vascular lesions; MedLite C6 and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos; and PicoSure product line for the treatment of tattoos, benign pigmented lesions, acne scars, fine lines, and wrinkles. The company also provides Icon aesthetic system for hair removal, wrinkle reduction, and scar and stretch mark treatment; Vectus diode laser for high volume hair removal; SculpSure hyperthermic laser treatment for LaserBodySculpting for non-invasive fat reduction; and MonaLisa Touch laser for gynecologic health. In addition, it markets radiofrequency energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry, and proctology. The company sells its products through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and South Korea, as well as through independent distributors in approximately 120 countries. Cynosure, Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.
People’s United Financial, Inc. (PBCT) traded within a range of $18.81 to $18.98 after opening the day at $18.85. The company has seen its stock decrease in value by -1.71% so far this year. The stock was up close to 0.64% on light volume in last trading session and closed at $18.86 per share. After the recent gain, the stock is currently holding -5.46% below its 52 week high of $20.13 and 43.45% above its 12-month low of $13.8. The shares are up by over 6.08% in the last three months, and the RSI indicator value of 49.64 is neither bullish nor bearish, tempting investors to stay on the sidelines.
People’s United Financial, Inc. operates as the bank holding company for People’s United Bank, National Association that provides commercial banking, retail banking, and wealth management services to individual, corporate, and municipal customers. The company operates in two segments, Commercial Banking and Retail Banking. The Commercial Banking segment offers commercial real estate lending, commercial and industrial lending, and commercial deposit gathering services. This segment also provides equipment financing; cash management, correspondent banking, and municipal banking services; and institutional trust, corporate trust, private banking, and insurance services. The Retail Banking segment offers consumer lending, including residential mortgage and home equity lending; and consumer deposit gathering services. This segment also provides brokerage, financial advisory, investment management, life insurance, and non-institutional trust services. In addition, the company offers online banking, investment trading, and telephone banking services. It operates through a network of 396 branches and 594 ATMs in Connecticut, southeastern New York, Massachusetts, Vermont, New Hampshire, and Maine. People’s United Financial, Inc. was founded in 1842 and is headquartered in Bridgeport, Connecticut.